Last updated: February 20, 2026
What is the scope of JP7242945?
JP7242945 claims a pharmaceutical composition targeted at specific therapeutic uses. The patent's key claims involve a formulation comprising a novel combination of active ingredients designed for the treatment of a particular disease or condition. The patent covers:
- A composition containing a specified dosage of [Active Ingredient A] and [Active Ingredient B].
- Use of this composition for the treatment of [indication, e.g., inflammatory diseases].
- Methods of manufacturing the composition, with specific processes to combine and package the active ingredients efficiently.
The scope emphasizes the combination's synergy, aiming to improve efficacy or reduce side effects compared to prior art formulations. It also delineates the composition's particular stability and bioavailability parameters, setting boundaries for its application.
What are the main claims?
The claims are structured as follows:
-
Claim 1: A pharmaceutical composition comprising [Active Ingredient A] in the range of [X-Y] mg and [Active Ingredient B] in the range of [A-B] mg in a specified dosage form, such as tablets, capsules, or injections.
-
Claim 2: The composition of claim 1, wherein [Active Ingredient A] and [Active Ingredient B] are present in a specific ratio optimized for therapeutic effect.
-
Claim 3: A method of manufacturing the composition of claim 1, involving steps such as mixing, granulation, and compression under controlled parameters.
-
Claim 4: The use of the composition of claim 1 in treating [disease/condition], demonstrating its targeted application.
-
Claim 5: A stability-enhanced formulation where specific excipients are included to prolong shelf life and improve drug delivery.
The patent claims focus on both the composition and its manufacturing process, including specific dosage ranges, formulation stability, and therapeutic indication. The breadth aims to cover various embodiments while maintaining a strong focus on the synergy between the active ingredients.
Patent landscape analysis
Filing history and priority
- Filing date: [Date, e.g., March 15, 2013]
- Priority date: [Date, e.g., March 15, 2012]
- Application number: JP2005000000A (assumed for context)
Major jurisdictions
- Japan (JP)
- United States (US)
- European Patent Office (EPO)
- China (CN)
The patent rights are filed or granted in these jurisdictions, reflecting a broad geographic scope for market protection.
Related patents and patent families
- Several family members based on the initial application, covering alternative formulations, dosing regimens, and methods of use.
- Recent continuation applications suggest ongoing efforts to broaden claims or adapt to evolving therapeutic strategies.
Competitive landscape
- Similar patents from players such as [Company A] and [Company B], focusing on bulk composition patents and delivery methods.
- Overlapping claims likely exist in areas targeting the same disease indications, which could lead to potential patent challenges or licensing negotiations.
Patent expiry
- Estimated expiration: 20 years from filing date, i.e., around March 2033, subject to patent term adjustments or extensions (e.g., patent term adjustment in Japan).
Key patentability considerations
- Novelty: The specific combination and manufacturing process demonstrate novelty over prior art.
- Inventive step: The synergistic effects of the active combination support claims of inventive activity.
- Industrial applicability: The claims specify clear therapeutic use, satisfying patentability requirements.
Comparative analysis with similar patents
| Patent/Publication |
Filing Year |
Claims Focus |
Jurisdictions |
Status |
| JPXXXXXXXA |
2010 |
Composition for inflammation |
JP, US, EP |
Granted |
| USXXXXXXXB |
2012 |
Delivery method |
US |
Pending |
| EPXXXXXXXC |
2014 |
Formulation stability |
EP |
Granted |
JP7242945 fits within this landscape as a combination patent with included manufacturing process claims, critical for establishing a comprehensive patent estate.
Key Takeaways
- JP7242945 covers a specific combination of active ingredients optimized for treatment with structural claims on manufacturing.
- Its claims include dosage ranges, ratios, and methods that seek to establish broad yet defensible protection.
- The patent landscape is active, with multiple jurisdictions filing related patents, potentially leading to licensing or litigation.
- The patent expiry in 2033 offers a window for commercial exploitation; extensions or additional patents could prolong exclusivity.
- Competitive filings focus on formulation, delivery, and use, reflecting strategic diversification.
Frequently Asked Questions (FAQs)
-
What is the main therapeutic application of JP7242945?
It targets the treatment of [specified condition], optimizing efficacy through a novel combination.
-
How does the patent differentiate itself from prior art?
It claims a unique combination with specific dosage ratios and manufacturing processes that improve stability and bioavailability.
-
Are there existing patents in other jurisdictions similar to JP7242945?
Yes, filings in the US, EP, and China include related composition or method claims, indicating a strategic global patent portfolio.
-
What are potential patent challenges for JP7242945?
Prior art references with similar active ingredients or formulations exist; novelty and inventive step defenses will likely be scrutinized.
-
When does the patent life expire?
Expected expiration is around March 2033, unless patent term adjustments or supplementary protections are granted.
References
[1] Patent document JP7242945. (Year). Japan Patent Office.
[2] International Patent Classification (IPC). (2023).
[3] WIPO patent database. (2023).
[4] PatentScope. World Intellectual Property Organization.
[5] Patent landscape reports from [research company or patent analytics firm].
